User profiles for "author:Alastair Wilkins"

Alastair Wilkins

Neurologist, University of Bristol
Verified email at bristol.ac.uk
Cited by 7280

[HTML][HTML] Mechanisms of oxidative damage in multiple sclerosis and a cell therapy approach to treatment

J Witherick, A Wilkins, N Scolding, K Kemp - Autoimmune diseases, 2010 - hindawi.com
Although significant advances have recently been made in the understanding and treatment
of multiple sclerosis, reduction of long-term disability remains a key goal. Evidence suggests …

[HTML][HTML] Cerebellar dysfunction in multiple sclerosis

A Wilkins - Frontiers in neurology, 2017 - frontiersin.org
Multiple sclerosis (MS) commonly affects the cerebellum causing acute and chronic
symptoms. Cerebellar signs contribute significantly to clinical disability, and symptoms such …

Primary progressive multiple sclerosis: progress and challenges

CM Rice, D Cottrell, A Wilkins… - Journal of Neurology …, 2013 - jnnp.bmj.com
Primary progressive multiple sclerosis (MS) has long been recognised as presenting great
difficulties to our management of what is increasingly a treatable neurological disease. Here …

Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived …

A Wilkins, H Majed, R Layfield, A Compston… - Journal of …, 2003 - Soc Neuroscience
Interactions of CNS cells lead to the establishment of complex neural systems. Specifically,
oligodendrocytes form myelin sheaths around axons that enable rapid electrical conduction …

Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis

JWL Brown, A Coles, D Horakova, E Havrdova… - Jama, 2019 - jamanetwork.com
Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

[HTML][HTML] Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro

A Wilkins, K Kemp, M Ginty, K Hares, E Mallam… - Stem cell …, 2009 - Elsevier
Bone marrow-derived mesenchymal stem cells (MSCs) are of therapeutic interest in a
variety of neurological diseases. In this study, we wished to determine whether human …

A role for oligodendrocyte‐derived IGF‐1 in trophic support of cortical neurons

A Wilkins, S Chandran, A Compston - Glia, 2001 - Wiley Online Library
Neurons and glia interact in the development of mammalian central nervous systems and in
the maintenance of stable myelinated axons. Recent evidence suggests a role for …

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

JL Jones, JM Anderson, CL Phuah, EJ Fox, K Selmaj… - Brain, 2010 - academic.oup.com
Abstract Treatment of early relapsing–remitting multiple sclerosis with the lymphocyte-
depleting humanized monoclonal antibody alemtuzumab (Campath [registered trade mark]) …

Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

T Kalincik, JWL Brown, N Robertson, M Willis… - The Lancet …, 2017 - thelancet.com
Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …

Mesenchymal stem cell‐secreted superoxide dismutase promotes cerebellar neuronal survival

K Kemp, K Hares, E Mallam, KJ Heesom… - Journal of …, 2010 - Wiley Online Library
J. Neurochem.(2010) 114, 1569–1580. Abstract It has been postulated that bone marrow‐
derived mesenchymal stem cells (MSCs) might be effective treatments for …